To view video, and read the full article visit URL http://crweselect.com/28515/stock-alerts/rmbs-astc-oxbt-crweselectcom-st...
Rambus, Inc. (NASDAQ: RMBS)
Rambus, Inc. - Symbol RMBS - announced today it has signed a patent license agreement with NVIDIA. The agreement covers the use of Rambus patented innovations in a broad range of integrated circuit (IC) products offered by NVIDIA. In addition, the two companies have settled all outstanding claims, including resolution of past use of Rambus' patented innovations. The term of this agreement is five years; other details are confidential.
Founded in 1990, RMBS is one of the world's premier technology licensing companies. As a company of inventors, Rambus focuses on the development of technologies that enrich the end-user experience of electronic systems. Its breakthrough innovations and solutions help industry-leading companies bring superior products to market. Rambus licenses both its world-class patent portfolio, as well as its family of leadership and industry-standard solutions. Rambus has offices in California, North Carolina, Ohio, India, Germany, Japan, Korea, and Taiwan.
For more information about RMBS please visit http://www.rambus.com
Astrotech Corporation (NASDAQ: ASTC)
Astrogenetix Corporation, a subsidiary of Astrotech Corporation - Symbol ASTC - has entered into a Space Act Agreement (SAA) with NASA, (National Aeronautics and Space Administration). This SAA commits to providing the critical resources needed to continue utilizing the International Space Station (ISS) and to further the development of important on-orbit microgravity vaccines and therapeutic drug experiments.
A subsidiary of ASTC , Astrogenetix is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity. The Company offers a turn-key platform for pre-flight sample preparation, flight hardware, mission planning and operations, crew training and certification processes needed within the highly regulated and complex environment of manned space flight.
For more information about ASTC please visit http://www.astrotechcorp.com
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT)
Oxygen Biotherapeutics, Inc. - Symbol OXBT - and privately held Aurum Biosciences Ltd. of Glasgow, Scotland, previously jointly reported they have signed a long-term agreement to develop a better tool for defining the extent of injury in acute ischemic stroke and for treating this emergency in the important early hours after the attack. At the center of both efforts is Oxygen Biotherapeutics' proprietary, perfluorocarbon-based Oxycyte emulsion, which is known for delivering large amounts of oxygen to the brain. The key to the diagnostic work lies in Aurum's proprietary GOLD (Glasgow Oxygen Level-Dependent) Magnetic Resonance Imaging (MRI) technology, which has already shown great promise in mapping potentially salvageable tissue in the brain after stroke in the brain.
Headquartered in Morrisville, NC, OXBT is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier product that is being formulated for both intravenous and topical delivery. Currently, Oxygen Biotherapeutics is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, personal care, and topical wound healing, and supports or collaborates with others researching the use of Oxycyte to treat other indications, including stroke. The company has commercialized its DERMACYTE(R) line of oxygen-rich skin care products.
For more information about OXBT please visit http://www.oxybiomed.com
To read the full article visit URL http://crweselect.com/28515/stock-alerts/rmbs-astc-oxbt-crweselectcom-st...
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.